Service interruption on Monday 11 July from 12:30 to 13:00: all the sites of the CCSD (HAL, Epiciences, SciencesConf, AureHAL) will be inaccessible (network hardware connection).
Skip to Main content Skip to Navigation
Journal articles

Que vaut une molécule ? Formulation de la valeur dans les projets de développement de nouveaux médicaments

Abstract : What’s a molecule worth? The formulation of value in drug development projects Following the advent of biotechnology and the amplifying calls for the transfer of knowledge from science to industry, the development of new drugs increasingly resorts to partnerships between pharmaceutical companies and start-ups stemming from public research. Such partnerships are market relations in which R&D (research & development) projects are bought and sold. How is the value of R&D projects constituted and measured in view of their exchange? The article addresses this question by focusing on the most widespread tool for the valuation of drug development projects: the discounted cash flow (DCF) formula. Widely used, the formula is also vividly criticized for the instability of the results that it produces and the too low values that it grants to exploratory projects. The study of the valuation practices that the formula instruments shows that the capacity of the formula to calculate hinges upon a metrological infrastructure and that, paradoxically, it is precisely because the formula produces “wrong” results that it “works”.
Document type :
Journal articles
Complete list of metadata
Contributor : Catherine Lucas Connect in order to contact the contributor
Submitted on : Wednesday, March 4, 2015 - 10:03:29 AM
Last modification on : Wednesday, November 17, 2021 - 12:33:10 PM

Links full text



Liliana Doganova. Que vaut une molécule ? Formulation de la valeur dans les projets de développement de nouveaux médicaments. Revue d'Anthropologie des Connaissances, Société d'Anthropologie des Connaissances, 2015, 9 (1), pp.17-38. ⟨10.3917/rac.026.0017⟩. ⟨hal-01122511⟩



Record views